Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion

Tofacitinib is a Jak inhibitor developed as a treatment for rheumatoid arthritis. Tofacitinib is metabolized mainly through hepatic CYP3A1/2, followed by CYP2C11. Rheumatoid arthritis tends to increase renal toxicity due to drugs used for long-term treatment. In this study, pharmacokinetic changes o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Sung Hun, Chang, Sun-Young, Kim, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464785/
https://www.ncbi.nlm.nih.gov/pubmed/32751547
http://dx.doi.org/10.3390/pharmaceutics12080714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464785/
https://www.ncbi.nlm.nih.gov/pubmed/32751547
http://dx.doi.org/10.3390/pharmaceutics12080714

Ejemplares similares